Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Roy

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Opinion in Oncology|November 1, 1995
Adjuvant systemic therapy for breast cancerJ A Roy, M J Piccart
Revue Medicale De Bruxelles|July 1, 1995
[Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases]J A Roy, M J Piccart
Revue Medicale De Bruxelles|September 1, 1996
[Systemic adjuvant therapy of breast cancer: myths and controversies]J A Roy, M J Piccart
Current Opinion in Oncology|November 1, 1996
Adjuvant systemic therapy for breast cancerM J Piccart, L Biganzoli, J A Roy
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?J A Roy, C A Sawka, K I Pritchard
Current Oncology (Toronto, Ont.)|August 13, 2009
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancerS Verma, S Sehdev, A Joy, et al.
Drugs|September 1, 1997
Breast cancer therapies in development. A review of their pharmacology and clinical potentialD de Valeriola, A Awada, J A Roy, et al.
Journal of Tropical Pediatrics|August 1, 1989
New parameters for evaluating oral rehydration therapy: one year's experience in a major urban hospital in ZaireM Moore, F Davachi, L Bongo, et al.
Seminars in Oncology|October 1, 1996
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancerM J Piccart-Gebhart, P Bruning, T Gamucci, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2001
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatinT L Moser, D J Kenan, T A Ashley, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|November 1, 1995
Adjuvant systemic therapy for breast cancerJ A Roy, M J Piccart
Revue Medicale De Bruxelles|July 1, 1995
[Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases]J A Roy, M J Piccart
Revue Medicale De Bruxelles|September 1, 1996
[Systemic adjuvant therapy of breast cancer: myths and controversies]J A Roy, M J Piccart
Current Opinion in Oncology|November 1, 1996
Adjuvant systemic therapy for breast cancerM J Piccart, L Biganzoli, J A Roy
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?J A Roy, C A Sawka, K I Pritchard
Current Oncology (Toronto, Ont.)|August 13, 2009
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancerS Verma, S Sehdev, A Joy, et al.
Drugs|September 1, 1997
Breast cancer therapies in development. A review of their pharmacology and clinical potentialD de Valeriola, A Awada, J A Roy, et al.
Journal of Tropical Pediatrics|August 1, 1989
New parameters for evaluating oral rehydration therapy: one year's experience in a major urban hospital in ZaireM Moore, F Davachi, L Bongo, et al.
Seminars in Oncology|October 1, 1996
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancerM J Piccart-Gebhart, P Bruning, T Gamucci, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2001
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatinT L Moser, D J Kenan, T A Ashley, et al.
Pageof 2